{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:39:40Z","timestamp":1778827180802,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The purpose of this study was to evaluate the feasibility and diagnostic performance of\u00a0prostate-specific membrane antigen (PSMA) based <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT-ultrasound (PET\/CT-US) or PET\/MRI-ultrasound (PET\/MRI-US) fusion targeted biopsy for intra-prostatic PET-positive lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From April 2018 to November 2019, we prospectively enrolled 55 candidates to perform PET\/CT-US or PET\/MRI-US fusion targeted biopsies for solitary PET-positive prostate lesions (two to four cores\/lesion). The positive rates of prostate cancer based on patients and biopsy cores were calculated respectively. With reference to the pathological results of biopsy cores, the MR signal characteristics in the area of the PET-positive lesion were analyzed for the patients who underwent PET\/MRI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 178 biopsy cores were taken on the 55 patients. One hundred forty-six biopsy cores (82.0%, 146\/178) from 51 (92.7%, 51\/55) patients were positive for prostate cancer; 47 (85.5%, 47\/55) were clinically significant prostate cancer. It is noteworthy that nine patients underwent both <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT and PET\/MRI examinations; the seven patients with prostate cancer showed abnormal MR signal in the area of the PET-positive lesion while the other two patients with prostatic hyperplasia and prostatitis showed normal MR signal in the area of the PET-positive lesion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study indicated that <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT-US or PET\/MRI-US fusion targeted prostate biopsies may be valuable for prostate cancer diagnosis and have a high detection rate of clinically significant prostate cancer for PET-positive lesions. PET\/MR can rule out some false PET-positive lesions, which may potentially reduce unnecessary prostate biopsies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.612157","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T06:01:44Z","timestamp":1614924104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["A Pilot Study of\u00a018F-DCFPyL PET\/CT or PET\/MRI and Ultrasound Fusion Targeted Prostate Biopsy for Intra-Prostatic PET-Positive Lesions"],"prefix":"10.3389","volume":"11","author":[{"given":"Yachao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongkai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baixuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.003","article-title":"Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update","volume":"177","author":"Thompson","year":"2007","journal-title":"J Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.08.007","article-title":"Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial","volume":"2","author":"Wegelin","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2016.10.040","article-title":"Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary","volume":"102","author":"Wang","year":"2017","journal-title":"Urology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous (68)Ga-PSMA HBED-CC PET\/MRI Improves the Localization of Primary Prostate Cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-Based [(18)F]DCFPyL PET\/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001846","article-title":"Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET\/CT","volume":"42","author":"Cornelis","year":"2017","journal-title":"Clin Nucl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.10.002","article-title":"[(18)F]-DCFPyL Positron Emission Tomography\/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience","volume":"4","author":"Bauman","year":"2018","journal-title":"Eur Urol Focus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"B9","first-page":"jnumed.119.235333","article-title":"PSMA PET\/CT and standard plus PET\/CT-Ultrasound fusion targeted prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsies","volume-title":"J Nuclear Med","author":"Liu","year":"2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.juro.2018.01.079","article-title":"(68)Ga-PSMA Positron Emission Tomography\/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study","volume":"200","author":"Lopci","year":"2018","journal-title":"J Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.225789","article-title":"(18)F-Choline PET\/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies","volume":"61","author":"Davenport","year":"2020","journal-title":"J Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/his.13712","article-title":"Defining clinically significant prostate cancer on the basis of pathological findings","volume":"74","author":"Matoso","year":"2019","journal-title":"Histopathology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.008","article-title":"Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies","volume":"68","author":"Arsov","year":"2015","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4081\/aiua.2014.4.311","article-title":"Repeated biopsy in the detection of prostate cancer: When and how many cores","volume":"86","author":"Scattoni","year":"2014","journal-title":"Archivio Italiano di Urol e Androl"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eururo.2014.10.026","article-title":"Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging\u2013Ultrasound Fusion Targeted Biopsy: A Systematic Review","volume":"68","author":"Valerio","year":"2015","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5152\/dir.2018.17422","article-title":"MRI\/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men","volume":"24","author":"Yarlagadda","year":"2018","journal-title":"Diagn Interv Radiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.169243","article-title":"Correlation of Intraprostatic Tumor Extent with (6)(8)Ga-PSMA Distribution in Patients with Prostate Cancer","volume":"57","author":"Rahbar","year":"2016","journal-title":"J Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/thno.15344","article-title":"(68)Ga-HBED-CC-PSMA PET\/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison","volume":"6","author":"Zamboglou","year":"2016","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.154336","article-title":"(1)(8)F-DCFBC PET\/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer","volume":"56","author":"Rowe","year":"2015","journal-title":"J Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002473","article-title":"68Ga-PSMA-11 PET\/MR Can Be False Positive in Normal Prostatic Tissue","volume":"44","author":"Ferraro","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2018.07.06","article-title":"Prostate imaging features that indicate benign or malignant pathology on biopsy","volume":"7","author":"Lovegrove","year":"2018","journal-title":"Transl Androl Urol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bju.14858","article-title":"Detection and localisation of primary prostate cancer using (68) Ga-PSMA PET\/CT compared with mpMRI and radical prostatectomy specimens","volume":"126","author":"Kalapara","year":"2020","journal-title":"BJU Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00259-013-2445-4","article-title":"PET\/MR in prostate cancer: technical aspects and potential diagnostic value","author":"Souvatzoglou","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04863-2","article-title":"(68)Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study","volume":"48","author":"Zhang","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1874471010666171101121803","article-title":"PET\/CT with 68Ga-PSMA In Prostate Cancer: Radiopharmaceutical Background And Clinical Implications","volume":"11","author":"Giovacchini","year":"2017","journal-title":"Curr Radiopharm"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2524-z","article-title":"PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics","volume":"37","author":"Eapen","year":"2019","journal-title":"World J Urol"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1097\/RCT.0000000000001116","article-title":"Comparison of MRI, PSMA PET\/CT, and Fusion PSMA PET\/MRI for Detection of Clinically Significant Prostate Cancer","volume-title":"J Comput assisted Tomography","author":"Arslan","year":"2020"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002526","article-title":"Comparing the Staging\/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET\/CT in Prostate Cancer: A Systematic Review and Meta-analysis","volume":"44","author":"Lin","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/bju.13247","article-title":"The value of magnetic resonance imaging and ultrasonography (MRI\/US)-fusion biopsy platforms in prostate cancer detection: a systematic review","volume":"117","author":"Gayet","year":"2016","journal-title":"BJU Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3791\/59231","article-title":"Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy","volume":"9","author":"Jayadevan","year":"2019","journal-title":"J Vis Exp"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/0391560319834490","article-title":"MRI ultrasound fusion biopsy in prostate cancer detection: Are randomized clinical trials reproducible in everyday clinical practice","volume":"86","author":"Cattarino","year":"2019","journal-title":"Urologia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.612157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T06:01:46Z","timestamp":1614924106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.612157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":33,"alternative-id":["10.3389\/fonc.2021.612157"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.612157","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"article-number":"612157"}}